Reva Medical (ASX:RVA) said today that the company launched its Fantom bioresorbable scaffold in Turkey. There are nearly 100 hospitals performing cardiac catheterizations in Istanbul, according to Reva. The San Diego, Calif.-based company highlighted Turkey as an important market for bioresorbable technologies, noting that it has a commercial distribution deal in the country with Kardionet Healthcare and […]
Pharmaceuticals
Aerie seeks FDA nod for Roclatan once-daily eye drop
Aerie Pharmaceuticals (NSDQ:AERI) said today that it submitted a new drug application to the FDA for its once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The company’s Roclatan product is a fixed-dose combination of two drugs – netarsudil and latanoprost. Aerie’s latest eye drug was proven to be safe and […]
Boston Scientific’s drug-coated balloon succeeds in femoropopliteal segment at one year
Data from Boston Scientific‘s (NYSE:BSX) Ranger SFA trial showed that treatment with its drug-coated balloon succeeded in the femoropopliteal segment after one year and resulted in greater rates of patency, with fewer interventions, compared to standard balloon angioplasty. The results, which were published this month in JACC: Cardiovascular Interventions, demonstrated that both groups of patients – […]
TapImmune adds cell therapy to peptide vaccine portfolio with Marker Therapeutics merger
TapImmune (NSDQ:TPIV) expanded its immuno-oncology capabilities today with a deal to acquire Marker Therapeutics and its clinical-stage, multi-antigen T cell therapy platform. Details regarding merger-related financing were not disclosed, but TapImmune said it is in talks with a syndicate of institutional investors to fund the company until 2020. “I believe that the new therapies we are […]
Baxter wins FDA nod for Spectrum IQ infusion system
Baxter (NYSE:BAX) said today that it won FDA clearance for its Spectrum IQ infusion system with Dose IQ safety software. The company touted its system as the first of its kind to include bi-directional electronic medical records integration. “EMR integration is an important step in making infusions safer, which is why Baxter designed the Spectrum IQ system with […]
Trump’s drug pricing plan called ‘non-event’ by analysts
President Donald Trump last week unveiled his administration’s plan to lower drug prices. But investors seemed relieved after the president made his highly anticipated announcement – stocks for large pharmaceutical companies and middlemen, like pharmacy benefit managers, were up on Friday. Trump did not commit to follow through with promises he made while campaigning for […]
HRS 2018: Study questions benefit of ablation over drug therapy for atrial fibrillation
Long-awaited data released today from a large clinical trial comparing catheter ablation with drug therapy in treating atrial fibrillation showed no significant benefit for ablation, according to Dr. Douglas Packer, who presented the findings today at the annual meeting of the Heart Rhythm Society in Boston. The 2,204-patient trial, sponsored by the National Institutes of […]
Mylan misses estimates on The Street with Q1 results
Shares in Mylan (NSDQ:MYL) rose slightly this morning after the pharmaceutical company reported its first-quarter financial results, missing analysts’ sales and earnings estimates. The company posted profits of $87.1 million, or 17¢ per share, on sales of $2.68 billion for the 3 months ended March 31, for bottom-line growth of 31% on sales loss of -1% […]
Manufacturing delays lead to Epipen shortage in U.S.
At least 400 people across the U.S. have had trouble getting their hands on an Epipen in recent weeks, according to a survey from the advocacy group Food Allergy Research & Education. Mylan (NSDQ:MYL), which makes the emergency allergy auto-injector, reportedly told the FDA months ago that manufacturing delays were straining its Epipen supply. Some patients […]
Update: Novartis paid more than $1m to consulting company linked to Trump attorney Michael Cohen
Updated 5/9 to include new information about Novartis’ payments to Essential Consultants. Novartis (NYSE:NVS) found itself in the middle of a national scandal today after it was revealed that the drugmaker paid more than $1 million to a consulting firm linked to President Donald Trump’s personal attorney, Michael Cohen. The shell company, Essential Consultants, was used by […]